Strides Pharma Science Limited (STAR) Q2 FY27 Financial Results: PAT ₹1,655 Cr & Revenue ₹12,654 Cr (2 announcements)

Strides Pharma reported Q1 FY27 revenue of ₹12,654 crores, up 13% YoY, driven by 17% growth in Ex-US markets. EBITDA rose 5.4% YoY to ₹2,298 crores, though margins were pressured by ~₹131 crore higher freight and operating costs. Operational PAT stood at ₹1,231 crores with EPS of ₹13.4, while reported PAT was ₹1,655 crores including a ₹208 crore gain from selling a stake in Pivot Path. The company reduced net debt by ₹119 crores to ₹14,246 crores, improving Net Debt/EBITDA to 1.52x. Management highlighted sustained growth in Ex-US markets and plans for new product launches in H2 FY27 to drive future revenue, particularly in controlled substances and specialty formats. They maintained a positive outlook on long-term growth despite external headwinds.

Strides Pharma Science reported Q1FY27 revenue of ₹12,654m, up 13% YoY, driven by 17% growth in Ex-US markets, while EBITDA rose 5.4% to ₹2,298m despite a ₹131m cost impact from geopolitical disruptions; operational PAT grew 8% to ₹1,231m and reported PAT surged 56.7% to ₹1,655m, reflecting a ₹1,000m gain from divesting a stake in Pivot Path, and the company highlighted ongoing cost optimization and sustainability progress.